IBRX270416P00006000
IBRX Apr 16 2027 6.00 Put
optionOPRA
InactiveSep 17, 2026
0.93USD+132.500%(+0.53)8Vol2OI
Loading…
Underlying
Underlying Price
$8.36
Type
Put
Strike
6
Expiration
Apr 16, 2027
DTE
178d
Moneyness
OTM
Intrinsic
$0.00
IBRX 6 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.25 | +400.00% | 1 | 71 |
| Oct 30, 2026 | 10d | $0.05 | +0.00% | 10 | 21 |
| Nov 6, 2026 | 17d | $0.05 | +0.00% | 10 | 15 |
| Nov 13, 2026 | 24d | $0.20 | -20.00% | 1 | 18 |
| Nov 20, 2026 | 31d | $0.10 | -23.08% | 250 | 3,143 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $0.59 | -34.44% | 5 | 354 |
| Apr 16, 2027 | 178d | $0.93 | +132.50% | 8 | 2 |
| May 21, 2027 | 213d | $0.75 | +0.00% | 2 | 1 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.